Boehringer Ingelheim to restructure executive board

Allan Hillgrove, head of pharmaceuticals and biopharma and a company veteran of 37 years, will retire at the end of the year and will be replaced by Carine Brouillon, who joined unlisted Boehringer from Johnson & Johnson(JnJ) in 2018.

Frankfurt: German drugmaker Boehringer Ingelheim will enter next year with a new-look executive board after the retirement of two of its top executives and another of the positions on the six-person executive board becoming redundant.

Allan Hillgrove, head of pharmaceuticals and biopharma and a company veteran of 37 years, will retire at the end of the year and will be replaced by Carine Brouillon, who joined unlisted Boehringer from Johnson & Johnson(JnJ) in 2018.

The head of Boehringer's animal health unit, Joachim Hasenmaier, will also retire at the end of the year, to be succeeded by Jean Scheftsik de Szolnok, currently head of Boehringer's French business.

Boehringer became the world's second-largest animal health company when it acquired Sanofi's Merial business in 2017 but it is set to drop a place in the ranking when Elanco wraps up its agreed purchase of Bayer's veterinary drugs business next year.

Read Also: Boehringer collaborates with MD Anderson to form virtual RnD center to advance new cancer therapies

Boehringer added that head of personnel Andreas Neumann would quit at the end of September because responsibilities for human resources will be shared by Chief Executive Hubertus von Baumbach and finance chief Michael Schmelmer.

A company spokesman declined to comment whether the departures were connected or coincidental.

Read Also: Boehringer buys up AMAL Therapeutics, eyes oncology combo strategy